Join MSF for a preview and discussion of Fire In The Blood and current U.S. government trade and global health policies with expert panelists as they examine this history and explain how the battle for affordable medicines and equal access for all patients continues today.
In order to prevent the diseases that killed many refugees in Yida camp, South Sudan, in 2012, Doctors Without Borders/Médecins Sans Frontières (MSF) has launched a water and sanitation program and begun a vaccination campaign for children. The campaign was pushed back to start now, during the logistically difficult rainy season, because MSF had to engage in lengthy negotiations to get the vaccine at an affordable price.
Doctors Without Borders/Médecins Sans Frontières (MSF) is proving two local health centers in Chiradzulu district, Malawi, with machines that test the blood of HIV patients. The machines will allow health workers to see how effective treatment has been and to make decisions based on those results. Up to now only large regional facilities could provide results like this.
Have you heard about the Trans-Pacific Trade Pact (TPP)? No? You're not alone. Negotiations are being conducted in secret, behind closed doors. But it's slated to become the most harmful trade agreement ever for access to medicines. It's not too late to act. Ask countries negotiating the TPP to protect people in developing countries. Click here for details.
On April 1, 2013, a landmark ruling by India's Supreme Court ensured continued access to affordable HIV medication for the millions affected by this disease, including the 220,000 patients that Doctors Without Borders/Médecins Sans Frontières (MSF) treats with generic HIV/AIDS medication. This access has been under threat for the past seven years by pharmaceutical company Novartis, which challenged a section of India's Patents Act that prevented the practice of "evergreening," or extending the patent of an existing medicine by modifying it slightly. By extending patents, pharmaceutical companies prevent the manufacture of generic drugs. The ruling by India's Supreme Court is a victory for those fighting for access to affordable medicine—at least, for the time being.
This short video report details a conference co-hosted at Mount Sinai School of Medicine’s Global Health Program in New York by Doctors Without Borders/Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi) that brought researchers, global health experts, and donors together to discuss the profound need for research and development initiatives in the field of neglected diseases. Since these diseases usually affect poor populations, research for finding better drugs and diagnostics for them is scarce. Click here for more details on the conference.
The first new drug approved to treat tuberculosis (TB) since 1963 could result in shorter treatment with less side effects and the opportunity to treat more people. For people with drug-resistant TB, it could present a new lifeline.
The January 2013 Month In Focus features brief reports on the following Doctors Without Borders/Médecins Sans Frontières (MSF) activities: assisting destitute civilians in Syria; a positive report on treatment of tuberculosis; an international conference in New York on fatally neglected diseases; monitoring the situation in Yida refugee camp in South Sudan; and preventing a measles epidemic among displaced children in the Democratic Republic of Congo.
Doctors Without Borders/Medecins Sans Frontieres (MSF), VII Photo, and UNION HZ present FATAL NEGLECT, a six-part documentary film project, that tells the stories of millions of patients left behind by the global health revolution. In Fatal Neglect: The Global Health Revolution’s Forgotten Patients, VII photographers Seamus Murphy, Venetia Dearden, Ron Haviv, and John Stanmeyer document the impact of multidrug-resistant tuberculosis, the three deadliest neglected tropical diseases—(visceral leishmaniasis (kala azar), Human African Trypanosomiasis (sleeping sickness), and Chagas—and vaccine-preventable diseases. The award-winning photojournalists traveled to Mali, Paraguay, South Sudan, and Tajikistan to capture the stories of frontline health workers trying to fight diseases that affect millions of people and kill hundreds of thousands each year yet garner little attention from drug developers, policy makers, or the mass media.
The lawsuit brought against the Indian Government by Swiss pharmaceutical company Novartis began in New Delhi on September 11. This new offensive follows the failure of a previous court case six years ago. Novartis is contesting part of Indian law on patents that enables Indian manufacturers to produce affordable generic drugs. Learn more.